People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dualitas Therapeutics, Inc. | — | Biotechnology | Series B | $32.6M | $150.4M | 2025 |
| Beryllium, LLC | — | Pharmaceuticals | Series A | $11.5M | $232.3M | 2014 |
Neil Weir at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Neil Weir on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Richard Murray | 1 | 5 |
| Mark McDade | 1 | 5 |
| Brian Hubbard | 1 | 4 |
| Thomas Hudson | 1 | 4 |
| Mirza Cifric | 1 | 3 |
| Nikola Trbovic | 1 | 3 |
| Jeffrey Newton | 1 | 3 |
| Lance Stewart | 1 | 2 |
| Johan Pontin | 1 | 1 |
| Brent Bannerman | 1 | 1 |
| Forbes Huang | 1 | 1 |
| Alicia Levey | 1 | 1 |
| Greg Lazar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.